Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$9.73-7.95%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CRVS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and its industry peers have been missing lately. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
CRVS — earnings miss
Dated 2026-08-06
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Why it matters: The trial tests soquelitinib against two chemotherapy choices in relapsed PTCL. It aims to enroll 150 people and track time without disease growth.
Watch forThe company says enrollment is on track for 150 people. There is no trial delay or safety pause.
Also watch forThe company reports a trial delay or safety pause. Enrollment toward 150 people is much slower.
Why it matters: The trial tests soquelitinib in about 200 people with atopic dermatitis. Strong results would build on early Phase 1 data.
Watch forAt Week 12, soquelitinib groups show a greater EASI score drop than placebo, with a clear dose trend.
Also watch forAt Week 12, soquelitinib groups do not improve EASI scores more than placebo. Or safety issues limit treatment.
Why it matters: Second-quarter research costs and net loss rose from a year earlier. The next report can show whether the cash burn is still rising.
Worry ifQ3 research costs or net loss rise year over year, and cash falls faster than needed for the stated Q2 2028 runway.
Less concerning ifQ3 research costs or net loss stay level or fall year over year, while management keeps the Q2 2028 runway.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$197 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $707 loss on $10,000 · 7.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,324 loss on $10,000 · 63.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.